Trials / Completed
CompletedNCT00002370
Study of Itraconazole in Patients With Advanced HIV Infection
Pharmacokinetics Study of Intravenous Itraconazole Followed by Oral Dosing at 200 Mg Twice Daily in Patients With Advanced HIV Infection
- Status
- Completed
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 36 (planned)
- Sponsor
- Janssen, LP · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
To demonstrate a dosage regimen for intravenous itraconazole that produces a plasma concentration range comparable to that obtained after currently used oral dosages of itraconazole oral solution; and to obtain preliminary safety data in patients with advanced HIV disease.
Detailed description
Patients will receive intravenous itraconazole solution twice daily for 2 days and then once daily for five additional days. Patients then randomized to receive twice-daily or once-daily itraconazole oral solution for an additional 28 days.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Itraconazole |
Timeline
- First posted
- 2001-08-31
- Last updated
- 2005-06-24
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT00002370. Inclusion in this directory is not an endorsement.